Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Terumo (JP:4543)
:4543
Holding JP:4543?
Track your performance easily
Earnings Data
Report Date
Feb 13, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
25.63Last Year’s EPS
20.03Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: -1.85%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call reflects a positive overall sentiment with record-breaking financial achievements and strategic innovations despite some regional challenges and cost concerns.Company Guidance
During Terumo's Q2 2025 earnings call, CFO Jin Hagimoto reported record-breaking first-half financial results, with a 15% year-over-year revenue growth reaching JPY 508.7 billion. The company's operating income and adjusted operating income also achieved record highs at JPY 87.7 billion and JPY 104.0 billion, respectively. The strong performance led to an upward revision of the full-year forecast, projecting record highs in sales and profit. The cardiovascular and blood center businesses were significant contributors, with foreign exchange effects adding JPY 2.2 billion in cash flow and JPY 3.0 billion in stock. The company also achieved a record half-year high in free cash flow, increased by JPY 44.6 billion from the previous year, due to successful working capital management and reduced capital investment. Looking forward, Terumo anticipates continued growth, leveraging both internal innovations and external partnerships, particularly in the cardiovascular and venous intervention markets.Record High Financial Metrics
Achieved record half-year highs in net sales, operating income, adjusted operating income, and net income with a 15% revenue growth year-over-year.
Strong Regional Performance
All regions, particularly the U.S. and Europe, showed steady growth with double-digit increases in revenue, led by the cardiovascular and blood center businesses.
Successful Innovation Strategy
Introduction of a Director of Innovation to enhance organizational reforms and promote innovation strategies, emphasizing both internal development and external partnerships.
Upward Revision of Full-Year Forecast
Full-year forecast revised upwards due to strong first-half performance, with expectations of record highs in sales and profit.
Significant Cash Flow Improvement
Free cash flow reached a record half-year high, increasing by JPY 44.6 billion from the same period last year.
---
JP:4543 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
JP:4543 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | ¥2970.50 | ¥2979.50 | +0.30% |
| Aug 08, 2024 | ¥2475.05 | ¥2473.55 | -0.06% |
| May 14, 2024 | ¥2650.70 | ¥2651.69 | +0.04% |
| Feb 07, 2024 | ¥2477.77 | ¥2514.45 | +1.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Terumo (JP:4543) report earnings?
Terumo (JP:4543) is schdueled to report earning on Feb 13, 2025, TBA Not Confirmed.
What is Terumo (JP:4543) earnings time?
Terumo (JP:4543) earnings time is at Feb 13, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Terumo stock?
The P/E ratio of Terumo is N/A.
What is JP:4543 EPS forecast?
JP:4543 EPS forecast for the fiscal quarter 2025 (Q3) is 25.63.
---